AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 0.1mg/kg intravenous in 100 ml serum physiologic
Study NCT03792841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Combined with acapatamab for investigational treatment of mCRPC
Study NCT03792841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Prophylaxis for acapatamab-related cytokine release syndrome.
Study NCT03792841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochrome P450 (CYP) Cocktail
Description: Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
Study NCT03198481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Centered Counseling Video
Description: Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
Study NCT03198481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Counseling Video
Description: Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
Study NCT03933319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
Study NCT02972151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment of TCM
Description: Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
Study NCT02972151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant treatment
Description: Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
Study NCT05747833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children Preparation With a Toy IV Catheter Before Peripheral Cannula application
Description: THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
Study NCT04124978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular advancement device
Description: use of prefabricated adjustable mandibular advancement device to improve OSA
Study NCT02039583 — intervention group
Intervention type: OTHER
Intervention: Smoke-free legislation
Description: The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
Study NCT01901211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming Intervention
Description: The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
Study NCT04444752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection.
Study NCT04444752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous(SC) injection
Study NCT02225028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Counseling
Description: Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
Study NCT03137485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional open lumbar discectomy
Description: Removal of single level lumbar disc herniation through conventional discectomy.
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1 gr intravenous
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: intravenous 1 gr
Study NCT01318187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg intravenous
Study NCT00804947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous busulfan and melphalan
Description: BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
Study NCT01470755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: salbutamol
Description: Metered dose inhaler, 100µg+300µg per puff, administered one day
Study NCT03137485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Endoscopic Translaminar lumbar discectomy.
Description: Removal of single level Lumbar disc herniation using endoscope.
Study NCT03137485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy Go system Endoscopy
Description: This system will be used to remove herniated disc in endoscopic group
Study NCT01470755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol - dose2
Description: Metered dose inhaler, 100µg+500µg per puff, administered one day
Study NCT01470755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol -dose3
Description: Metered dose inhaler, 200µg+600µg per puff, administered one day
Study NCT01470755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: salbutamol -dose4
Description: Metered dose inhaler, 200µg+200µg per puff, administered one day
Study NCT06532955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis using Microsure Motion Stabilizer
Description: The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure.
Study NCT06532955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphaticovenous anastomosis (manual)
Description: Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
Study NCT01531868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Video of physician
Study NCT04297540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS group
Description: Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
Study NCT04297540 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS group
Description: Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
Study NCT01559402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP and 100% oxygen
Description: During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
Study NCT01559402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP and 31% oxygen
Description: During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
Study NCT01559402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No CPAP and 100% oxygen
Description: This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
Study NCT04318340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapered applicator
Description: An applicator inserted in 2 steps that tapers at the distal vagina
Study NCT04318340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard applicator
Description: A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
Study NCT03408912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FFR
Description: FFR from CMR compared to invasive FFR
Study NCT01752192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation programme
Description: Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
Study NCT00647712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium Extended-Release Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT00647712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote ER® Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT01574300 — intervention group
Intervention type: OTHER
Intervention: therapeutic interventions
Description: All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
Study NCT00110617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Description: Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
Study NCT00110617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
Study NCT02378168 — intervention group
Intervention type: OTHER
Intervention: no intervention; retrospective study
Study NCT01093352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar-decortication.
Description: Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
Study NCT01823848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phosphate enema
Description: Rectally administered medication to treat constipation
Study NCT01823848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate enema
Description: Rectally administered medication to treat constipation
Study NCT01823848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline enema
Description: Rectally administered medication to treat constipation
Study NCT01823848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline enema
Description: Rectally administered medication to treat constipation
Study NCT01823848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral oil enema
Description: Mineral oil enema administered to treat constipation. 66ml per rectum
Study NCT01823848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral oil enema
Description: Mineral oil enema administered to treat constipation. 66ml per rectum
Study NCT01774565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Automated Closed-Loop Insulin Delivery
Study NCT01774565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional insulin therapy
Study NCT00586807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stable amino acid isotopes
Description: Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
Study NCT03623776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
Study NCT03623776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
Study NCT03623776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
Study NCT03623776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgery
Description: Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
Study NCT03590847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
Study NCT02597283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biguard sirolimus-eluting bifurcation stent system
Description: PCI with Biguard sirolimus-eluting bifurcation stent system
Study NCT02597283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent system
Description: PCI with sirolimus-eluting stent system
Study NCT00769782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
Study NCT01972542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Oral fat tolerance test
Study NCT01972542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral fat tolerance test
Study NCT00395200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSC Treatment
Description: Intravenous administration of up to 2x10\^6 autologous MSCs per kg
Study NCT00640822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol plus hydrocortisone ointment vehicle
Description: Once daily application for up to 8 weeks
Study NCT00640822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacalcitol Ointment
Description: Once daily application for up to 8 weeks
Study NCT00640822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus hydrocortisone ointment
Description: Once daily application for up to 8 weeks
Study NCT02476734 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
Study NCT03855124 — intervention group
Intervention type: DEVICE
Intervention: Posture shirt
Description: Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
Study NCT04514770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: rupture of membrane early and late
Study NCT00787670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
Study NCT00787670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass surgery
Description: gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
Study NCT00787670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Control Group
Description: During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
Study NCT02666365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus infusion of Cefazolin
Description: Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
Study NCT02666365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of Cefazolin
Description: Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure